Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Embolization of post-partial nephrectomy upper calyceal-perirenal urinary fistula using onyx-34: A novel application of a (pseudo-) liquid embolic agent.

Indian journal of urology : IJU : journal of the Urological Society of India·2026
Same author

Transcriptomic deconvolution reveals prognostic immune signatures and immunotherapy-responsive subtypes in male breast cancer.

Breast cancer research : BCR·2026
Same author

Toward a PSMA PET-mpMRI pathway for biopsy decision-making in men with suspected prostate cancer: interim results from the prospective BIOPSTAGE trial.

Frontiers in oncology·2026
Same author

Correction: Prostatic artery embolization with glue for benign prostatic hyperplasia in elderly patients: three-year results.

La Radiologia medica·2025
Same author

Prostatic artery embolization with glue for benign prostatic hyperplasia in elderly patients: three-year results.

La Radiologia medica·2025
Same author

Exploring the promoter regions of cancer predisposition genes in patients with triple-negative breast cancer reveals the presence of rare germline variants.

The oncologist·2025

Related Experiment Video

Updated: Mar 8, 2026

Cell-Free DNA Integrity Analysis in Urine Samples
07:58

Cell-Free DNA Integrity Analysis in Urine Samples

Published on: January 5, 2017

14.4K

Cell-Free DNA Integrity Analysis in Urine Samples.

Valentina Casadio1, Samanta Salvi2, Filippo Martignano2

  • 1Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS; valentina.casadio@irst.emr.it.

Journal of Visualized Experiments : Jove
|January 25, 2017
PubMed
Summary
This summary is machine-generated.

Urine cell-free DNA integrity shows promise as a non-invasive biomarker for early detection of prostate and bladder cancers. This novel test analyzes DNA fragmentation patterns to differentiate cancer patients from healthy individuals.

More Related Videos

Detection of Cell-Free DNA in Blood Plasma Samples of Cancer Patients
08:25

Detection of Cell-Free DNA in Blood Plasma Samples of Cancer Patients

Published on: September 9, 2020

11.9K
Uracil-DNA Glycosylase Assay by Matrix-assisted Laser Desorption/Ionization Time-of-flight Mass Spectrometry Analysis
12:19

Uracil-DNA Glycosylase Assay by Matrix-assisted Laser Desorption/Ionization Time-of-flight Mass Spectrometry Analysis

Published on: April 22, 2022

4.4K

Related Experiment Videos

Last Updated: Mar 8, 2026

Cell-Free DNA Integrity Analysis in Urine Samples
07:58

Cell-Free DNA Integrity Analysis in Urine Samples

Published on: January 5, 2017

14.4K
Detection of Cell-Free DNA in Blood Plasma Samples of Cancer Patients
08:25

Detection of Cell-Free DNA in Blood Plasma Samples of Cancer Patients

Published on: September 9, 2020

11.9K
Uracil-DNA Glycosylase Assay by Matrix-assisted Laser Desorption/Ionization Time-of-flight Mass Spectrometry Analysis
12:19

Uracil-DNA Glycosylase Assay by Matrix-assisted Laser Desorption/Ionization Time-of-flight Mass Spectrometry Analysis

Published on: April 22, 2022

4.4K

Area of Science:

  • Urology
  • Molecular Diagnostics
  • Oncology

Background:

  • Circulating cell-free DNA (cfDNA) in plasma/serum is a known cancer biomarker source.
  • Urine cell-free (UCF) DNA potential for cancer diagnostics is under-explored.
  • Cancer cells may release longer cfDNA fragments compared to normal apoptotic cells.

Purpose of the Study:

  • Evaluate UCF DNA integrity as an early diagnostic marker for prostate and bladder cancers.
  • Develop a non-invasive method to distinguish cancer patients from healthy individuals.
  • Assess the utility of UCF DNA integrity for urologic malignancy detection.

Main Methods:

  • Proposed UCF DNA integrity analysis using quantitative real-time PCR.
  • Targeted four specific gene sequences (c-MYC, BCAS1, HER2, AR) longer than 250 bp.
  • Selected genes with known increased copy numbers in bladder and prostate cancers.

Main Results:

  • UCF DNA integrity analysis demonstrated potential in distinguishing cancer patients.
  • The method is adaptable, allowing for substitution of target genes.
  • UCF DNA integrity testing is non-invasive, rapid, and requires minimal urine volume.

Conclusions:

  • UCF DNA integrity serves as a promising non-invasive biomarker for early urologic cancer diagnosis.
  • The proposed real-time PCR method offers a flexible and efficient approach.
  • Further characterization of UCF DNA is warranted for broader clinical application.